For more than 15 years, Dr. Aishen Gong has presided over the DMPK and toxicology department of three drug R&D enterprises and was responsible for the preclinical PK and tox evaluation in support of drug discovery and development. She was involved in the preclinical development and IND application of more than 20 class 1.1 innovative drugs. Dr. Gong has comprehensive experiences in biological evaluation, preclinical project management and IND application. She is also capable of providing technical support for phase I clinical pharmacokinetics and generic drug consistency studies.